Pheochromocytoma Market Analysis - Global Industry Size, Share, Trends and Forecast 2022 - 2030
CHAPTER 1. Industry Overview of Pheochromocytoma Market
1.1. Definition and Scope
1.1.1. Definition of Pheochromocytoma
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Pheochromocytoma Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Pheochromocytoma Market By Diagnosis
1.2.3. Pheochromocytoma Market By Treatment
1.2.4. Pheochromocytoma Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Pheochromocytoma Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Pheochromocytoma Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Pheochromocytoma Market By Diagnosis
4.1. Introduction
4.2. Pheochromocytoma Revenue (USD Million) By Diagnosis
4.2.1. Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
4.2.2. Laboratory Tests
4.2.2.1. Laboratory Tests Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.3. Genetic Testing
4.2.3.1. Genetic Testing Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.4. Imaging Tests
4.2.4.1. Imaging Tests Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 5. Pheochromocytoma Market By Treatment
5.1. Introduction
5.2. Pheochromocytoma Revenue (USD Million) By Treatment
5.2.1. Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
5.2.2. Medications
5.2.2.1. Medications Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Surgery
5.2.3.1. Surgery Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. North America Pheochromocytoma Market By Country
6.1. North America Pheochromocytoma Overview
6.2. U.S.
6.2.1. U.S. Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
6.2.2. U.S. Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
6.3. Canada
6.3.1. Canada Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
6.3.2. Canada Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
6.4. North America PEST Analysis
CHAPTER 7. Europe Pheochromocytoma Market By Country
7.1. Europe Pheochromocytoma Overview
7.2. U.K.
7.2.1. U.K. Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
7.2.2. U.K. Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
7.3. Germany
7.3.1. Germany Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
7.3.2. Germany Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
7.4. France
7.4.1. France Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
7.4.2. France Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
7.5. Spain
7.5.1. Spain Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
7.5.2. Spain Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
7.6. Rest of Europe
7.6.1. Rest of Europe Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
7.6.2. Rest of Europe Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
7.7. Europe PEST Analysis
CHAPTER 8. Asia Pacific Pheochromocytoma Market By Country
8.1. Asia Pacific Pheochromocytoma Overview
8.2. China
8.2.1. China Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
8.2.2. China Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
8.3. Japan
8.3.1. Japan Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
8.3.2. Japan Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
8.4. India
8.4.1. India Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
8.4.2. India Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
8.5. Australia
8.5.1. Australia Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
8.5.2. Australia Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
8.6. South Korea
8.6.1. South Korea Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
8.6.2. South Korea Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
8.7.2. Rest of Asia-Pacific Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Pheochromocytoma Market By Country
9.1. Latin America Pheochromocytoma Overview
9.2. Brazil
9.2.1. Brazil Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
9.2.2. Brazil Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
9.3. Mexico
9.3.1. Mexico Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
9.3.2. Mexico Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
9.4. Rest of Latin America
9.4.1. Rest of Latin America Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
9.4.2. Rest of Latin America Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa Pheochromocytoma Market By Country
10.1. Middle East & Africa Pheochromocytoma Overview
10.2. GCC
10.2.1. GCC Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
10.2.2. GCC Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
10.3. South Africa
10.3.1. South Africa Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
10.3.2. South Africa Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Pheochromocytoma Revenue (USD Million) and Forecast By Diagnosis, 2018-2030
10.4.2. Rest of Middle East & Africa Pheochromocytoma Revenue (USD Million) and Forecast By Treatment, 2018-2030
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of Pheochromocytoma Market
11.1. Pheochromocytoma Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Pheochromocytoma Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. AstraZeneca
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Million), 2021
12.1.3.2. AstraZeneca 2021 Pheochromocytoma Business Regional Distribution
12.1.4. Product/Service and Specification
12.1.5. Recent Developments & Business Strategy
12.1.6. Manufacturing Plant Footprint Analysis
12.2. Exelixis, Inc.
12.3. Jubilant Cadista
12.4. MediaPharma s.r.l.
12.5. Novartis AG
12.6. Pfizer Inc.
12.7. Progenics Pharmaceuticals, Inc.
12.8. Teva Pharmaceutical Company Limited
12.9. Valeant Pharmaceuticals International, Inc.
12.10. Zydus Cadila
Frequently Asked Questions
How much was the global pheochromocytoma market size in 2021?
The global pheochromocytoma market size in 2021 was accounted to be USD 2,989 Million.
What will be the projected CAGR for global pheochromocytoma market during forecast period of 2022 to 2030?
The projected CAGR pheochromocytoma market during the analysis period of 2022 to 2030 is 4.2%.
Which are the prominent competitors operating in the market?
The prominent players of the global pheochromocytoma market are AstraZeneca, Exelixis, Inc., Jubilant Cadista, MediaPharma s.r.l., Novartis AG, Pfizer Inc., Progenics Pharmaceuticals, Inc., Teva Pharmaceutical Company Limited, Valeant Pharmaceuticals International, Inc., and Zydus Cadila.
Which region held the dominating position in the global pheochromocytoma market?
North America held the dominating pheochromocytoma during the analysis period of 2022 to 2030.
Which region exhibited the fastest growing CAGR for the forecast period of 2022 to 2030?
Asia-Pacific region exhibited fastest growing CAGR for pheochromocytoma during the analysis period of 2022 to 2030.
What are the current trends and dynamics in the global pheochromocytoma market?
Surging prevalence of pheochromocytoma, growing incidence rate of tumors and rapid change in lifestyles drives the growth of global pheochromocytoma market.
By segment diagnosis, which sub-segment held the maximum share?
Based on diagnosis, imaging tests segment held the maximum share pheochromocytoma market in 2021.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
